AIVITA Biomedical Announces 96% Immune Response Against SARS-CoV-2 in Phase 2 Clinical Trial of a Personalized Vaccine
AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Present at World Vaccine Congress
AIVITA Biomedical Chief Medical Officer Dr. Robert Dillman to Deliver Keynote at World Immunotherapy Congress
AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Present at World Vaccine Congress
AIVITA Biomedical Chief Medical Officer Dr. Robert Dillman to Deliver Keynote at World Immunotherapy Congress
